CRISPR-Cas13a-based dual-channel AND-logic gated biosensor for the simultaneous assay of APE1 and miRNA-224

Tongyan Yuan; Jinlian Du; Jingjing Hu; Jiaming Luo; Xingxiang Pu; Xinyue Zhu; Bojie Chen; Yuling Teng; Han Li; Sheng Li; Ling Jiang; Erhu Xiong

doi:10.1039/d5cc03222a

CRISPR-Cas13a-based dual-channel AND-logic gated biosensor for the simultaneous assay of APE1 and miRNA-224

Chem Commun (Camb). 2025 Jul 4. doi: 10.1039/d5cc03222a. Online ahead of print.

Authors

Tongyan Yuan¹, Jinlian Du¹, Jingjing Hu¹, Jiaming Luo¹, Xingxiang Pu², Xinyue Zhu¹, Bojie Chen¹, Yuling Teng¹, Han Li¹, Sheng Li¹, Ling Jiang¹, Erhu Xiong¹

Affiliations

¹ Key Laboratory of Chemical Biology & Traditional Chinese Medicine Research, Ministry of Education, College of Chemistry and Chemical Engineering, Hunan Normal University, Changsha 410081, China. ljiang630@163.com.
² Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China. puxingxiang@hnca.org.cn.

PMID: 40613420
DOI: 10.1039/d5cc03222a

Abstract

Simultaneous detection of multiple targets is of great significance for the precise diagnosis of diseases. Herein, we report a dual-channel AND-logic gated biosensing platform based on the CRISPR-Cas13a system for the simultaneous detection of APE1 and miRNA-224, which showed superior specificity, sensitivity and potential for practical applications. Our study not only expands the CRISPR toolbox beyond nucleic acid assay but also establishes a new paradigm for multi-analyte diagnostic systems.